Luen, S. J., Bajaj, P., Blinman, P., Desai, J., Frentzas, S., Gan, H. K., Estacio, O., Harris, S. J., Markman, B., Millward, M., Shannon, C. M., Ebersbach, H., Berger, C., Renner, C. (2026). Re-sensitizing PD-1/PD-L1 relapsed/refractory solid tumors: Phase 1a results of IOS-1002, a LILRB1/2 and KIR3DL1 checkpoint inhibitor, in combination with pembrolizumab.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.2501